NAGE
Niagen Bioscience Inc NASDAQ Listed Jun 24, 2015$3.38
-0.88%
vs $3.41
Mkt Cap $288.8M
52w Low $3.37
0.1% of range
52w High $14.41
50d MA $4.07
200d MA $5.92
P/E (TTM)
15.5x
EV/EBITDA
10.5x
P/B
3.5x
Debt/Equity
0.0x
ROE
22.7%
P/FCF
22.0x
RSI (14)
42.00
ATR (14)
$0.14
Beta
2.23
50d MA
$4.07
200d MA
$5.92
Avg Volume
864.6K
Niagen Bioscience Inc is a bioscience company dedicated to healthy aging. The Company leads research on nicotinamide adenine dinucleotide.
10900 Wilshire Blvd, Suite 600 · Los Angeles, CA 90024 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 6, 2026 | AMC | 0.06 | 0.07 | +16.7% | 4.97 | -12.3% | -15.7% | -0.5% | -4.6% | -3.3% | -2.3% | — |
| Mar 4, 2026 | AMC | 0.02 | 0.03 | +50.0% | 4.94 | +15.2% | +3.2% | -0.8% | +1.0% | +2.2% | -6.3% | — |
| Nov 4, 2025 | AMC | 0.01 | 0.05 | +233.3% | 6.95 | +8.6% | -1.0% | -4.1% | +3.6% | +3.8% | +0.8% | — |
| Aug 6, 2025 | AMC | 0.02 | 0.04 | +100.0% | 9.40 | +19.1% | +2.2% | +1.2% | +0.9% | +4.5% | -1.4% | — |
| May 7, 2025 | AMC | 0.02 | 0.04 | +100.0% | 8.45 | +5.2% | +9.3% | -3.1% | +4.9% | +3.6% | +3.8% | — |
| Mar 4, 2025 | AMC | 0.02 | 0.03 | +50.0% | 5.60 | +19.8% | +52.7% | -10.1% | +0.1% | +2.3% | +0.3% | — |
| Oct 31, 2024 | AMC | 0.01 | 0.02 | +100.0% | 3.49 | +18.1% | +67.9% | -2.0% | +6.4% | +14.4% | -3.1% | — |
| Jun 30, 2024 | AMC | -0.02 | -0.00 | +99.0% | — | — | — | — | — | — | — | — |
| Mar 31, 2024 | AMC | -0.02 | -0.01 | +67.5% | — | — | — | — | — | — | — | — |
| Dec 31, 2023 | AMC | -0.02 | 0.00 | +106.7% | — | — | — | — | — | — | — | — |
| Sep 30, 2023 | AMC | -0.03 | -0.01 | +57.3% | — | — | — | — | — | — | — | — |
| Jun 30, 2023 | AMC | -0.04 | -0.03 | +27.0% | 1.57 | -1.3% | -1.3% | +3.2% | -2.5% | +1.3% | +3.8% | — |
| Mar 31, 2023 | AMC | — | -0.03 | — | 1.53 | +1.3% | -1.3% | -4.0% | +2.1% | -2.0% | -2.1% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 31 | Canaccord Genuity | Maintains | Buy → Buy | — | $4.28 | $4.36 | +1.9% | +3.0% | +2.5% | -3.1% | +2.1% | +0.0% |
| Mar 5 | Canaccord Genuity | Maintains | Buy → Buy | — | $4.94 | $5.69 | +15.2% | +3.2% | -0.8% | +1.0% | +2.2% | -6.3% |
| Nov 5 | Canaccord Genuity | Maintains | Buy → Buy | — | $6.95 | $7.55 | +8.6% | -1.0% | -4.1% | +3.6% | +3.8% | +0.8% |
| Aug 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.73 | $9.94 | +2.2% | +0.9% | +4.5% | -1.4% | -4.1% | +3.2% |
| Jun 10 | Canaccord Genuity | Maintains | Buy → Buy | — | $13.43 | $13.43 | +0.0% | +0.7% | +4.1% | +0.5% | -3.6% | +3.7% |
| Jun 6 | Roth Capital | Maintains | Buy → Buy | — | $11.51 | $11.94 | +3.7% | +12.5% | +3.7% | +0.7% | +4.1% | +0.5% |
| Apr 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.62 | $5.96 | +6.0% | -3.6% | +11.4% | -6.1% | +4.6% | +3.5% |
| Mar 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.77 | $6.60 | -2.5% | +1.9% | -0.4% | +3.1% | -6.4% | -9.2% |
| Mar 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.84 | $7.83 | -0.1% | +1.3% | -0.9% | -1.7% | -1.3% | +1.4% |
| Mar 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.70 | $7.80 | +1.3% | +2.3% | +0.3% | -0.9% | -1.4% | +1.6% |
| Mar 5 | Ladenburg Thalmann | Maintains | Buy → Buy | — | $5.60 | $6.71 | +19.8% | +52.7% | -10.1% | +0.1% | +2.3% | +0.3% |
| Nov 6 | Roth MKM | Maintains | Buy → Buy | — | $6.11 | $6.44 | +5.4% | +14.4% | -3.1% | -4.0% | +7.8% | +3.4% |
| Nov 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.86 | $5.72 | -2.4% | -2.0% | +6.4% | +14.4% | -3.1% | -4.0% |
No insider trades available.
8-K · 2.02
!! High
Niagen Bioscience Inc -- 8-K 2.02: Earnings Results
Niagen Bioscience released earnings results, with detailed financial performance available in the attached press release, though specific metrics require review of the full disclosure.
May 6
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
ZEOX gains credibility and marketing exposure by partnering with A4M at a major longevity conference, positioning itself alongside established public competitors to attract institutional investors and accelerate clinical advancement.
Mar 31
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
NAGE's $10 billion share buyback authorization signals management confidence and will reduce share count, boosting earnings per share and potentially supporting stock price during market volatility.
Mar 19
8-K · 7.01
! Medium
Niagen Bioscience, Inc. -- 8-K 7.01: Regulation FD Disclosure
Niagen Bioscience released a corporate presentation on March 4, 2026, providing updated company information to investors and the public through regulatory disclosure channels.
Mar 4
8-K · 8.01
!! High
Niagen Bioscience, Inc. -- 8-K 8.01: Material Event / Announcement
Niagen Bioscience agreed to sell its analytical reference standards and services business to VHG Labs, a LGC Group subsidiary, in an all-cash transaction that will streamline operations.
Feb 26
8-K · 5.02
!!! Very High
Entera Bio Ltd. -- 8-K 5.02: Executive Change
Steven D. Rubin's appointment as a Class III director at Entera Bio (ENTX) effective February 2026 expands board oversight and may signal management's confidence in governance structure during potential strategic initiatives.
Feb 4
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Steelpeak Wealth, Llc | 3,373,000 | $15M | New | Mar 2026 |
| 2 | Morgan Stanley | 1,760,248 | $11M | Added | Dec 2025 |
| 3 | Arrowstreet Capital, Limited Partnership | 2,378,437 | $10M | Added | Mar 2026 |
| 4 | Vanguard Capital Management Llc | 2,149,277 | $9M | New | Mar 2026 |
| 5 | Qube Research & Technologies Ltd | 1,714,639 | $8M | Added | Mar 2026 |
| 6 | Ubs Group Ag | 1,405,531 | $6M | — | Mar 2026 |
| 7 | Renaissance Technologies Llc | 1,328,843 | $6M | Added | Mar 2026 |
| 8 | Vanguard Portfolio Management Llc | 1,221,494 | $5M | New | Mar 2026 |
| 9 | Eversource Wealth Advisors, Llc | 54,737 | $5M | Added | Mar 2026 |
| 10 | Aqr Capital Management Llc | 1,031,335 | $5M | Added | Mar 2026 |
| 11 | Sei Investments Co | 971,574 | $4M | Added | Mar 2026 |
| 12 | Connor, Clark & Lunn Investment Management Ltd. | 584,229 | $4M | Reduced | Dec 2025 |
| 13 | Op Asset Management Ltd | 668,824 | $3M | Added | Mar 2026 |
| 14 | Millennium Management | 551,349 | $2M | Reduced | Mar 2026 |
| 15 | Citadel Advisors Llc | 530,477 | $2M | Added | Mar 2026 |
| 16 | Jane Street Group, Llc | 357,238 | $2M | Added | Dec 2025 |
| 17 | Los Angeles Capital Management Llc | 481,442 | $2M | Added | Mar 2026 |
| 18 | Victory Capital Management Inc | 425,422 | $2M | Added | Mar 2026 |
| 19 | Northern Trust Corp | 396,067 | $2M | Reduced | Mar 2026 |
| 20 | Jpmorgan Chase & Co | 326,711 | $1M | Reduced | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$288.8M
Enterprise Value
$224.0M
P/E (TTM)
15.49x
Forward P/E
13.17x
PEG Ratio
0.24x
P/B
3.50x
P/S
2.21x
P/FCF
21.97x
EV/EBITDA
10.47x
Shares Out
85.4M
Financials (TTM)
Revenue
$130.4M
Net Income
$18.6M
EBITDA
$21.4M
Free Cash Flow
$13.1M
Op Cash Flow
$13.4M
EPS Basic
$0.22
EPS Diluted
$0.22
EPS Forward
$0.26
Gross Margin
64.3%
Op Margin
8.5%
Net Margin
14.3%
Balance Sheet
Total Assets
$106.4M
Total Liab.
$29.9M
Total Equity
$76.5M
Cash
$64.8M
LT Debt
$0
Book Value/Sh
$0.97
Debt/Equity
0.04x
Current Ratio
4.86
Quick Ratio
3.83
Returns & Growth
ROE
22.7%
ROA
16.3%
ROIC
15.6%
Rev Growth YoY
+29.9%
EPS Growth YoY
+120.0%
Price Returns
2W
+1.6%
1M
-18.4%
3M
-23.6%
6M
-43.0%
12M
-64.3%
Technicals
52W High
$14.41
52W Low
$3.37
50d MA
$4.07
200d MA
$5.92
RSI (14)
42.00
ATR (14)
$0.14
Beta
2.23
Avg Volume
865K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$14.00
High
$14.00
Low
$14.00
Median
$14.00
Data updated apr 26, 2026 2:09pm
· Source: financialmodelingprep.com